Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
EPRX has more than doubled off its 52-week low of $3.667.
Summary
Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as its new Chief Medical Officer, replacing the retiring Dr. Mark Kowalski, who will transition to a senior consultant role.
Key Events · Executive and Board Changes · EPRX
-
New Chief Medical Officer Appointed
Dr. Jeymi Tambiah has been appointed as the new Chief Medical Officer, bringing over 18 years of experience in clinical development, medical, and regulatory strategy.
-
Outgoing CMO Retires
Dr. Mark Kowalski, the current CMO, is retiring but will serve as a senior consultant to ensure a smooth transition.
-
Strengthens Clinical Leadership
Dr. Tambiah's background as a Board Certified Cardiothoracic Surgeon and his track record in advancing immunology programs are expected to drive late-stage development and pipeline expansion, particularly for EP-104GI in Eosinophilic Esophagitis.
Analysis · EPRX · Life Sciences
The appointment of Dr. Jeymi Tambiah as Chief Medical Officer is a significant executive leadership change for Eupraxia Pharmaceuticals, a clinical-stage biotechnology company. Dr. Tambiah brings extensive experience in clinical development, medical, and regulatory strategy, which is crucial as the company advances its EP-104GI program in Eosinophilic Esophagitis and expands its gastroenterology pipeline. The smooth transition with the retiring CMO, Dr. Mark Kowalski, serving as a consultant, mitigates potential disruption and ensures continuity in clinical strategy.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EPRX was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $485.3M. The 52-week trading range was $3.67 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.